These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 25486910)

  • 21. MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2.
    Park DH; Jeon HS; Lee SY; Choi YY; Lee HW; Yoon S; Lee JC; Yoon YS; Kim DS; Na MJ; Kwon SJ; Kim DS; Kang J; Park JY; Son JW
    Int J Oncol; 2015 Oct; 47(4):1545-53. PubMed ID: 26238771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
    Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H
    Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
    Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.
    Xu K; Liu B; Liu Y
    Mol Med Rep; 2015 Jul; 12(1):995-1001. PubMed ID: 25683840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
    Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
    Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
    [No Abstract]   [Full Text] [Related]  

  • 27. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
    Fujii A; Harada T; Iwama E; Ota K; Furuyama K; Ijichi K; Okamoto T; Okamoto I; Takayama K; Nakanishi Y
    Cancer Genet; 2015 May; 208(5):271-8. PubMed ID: 25682017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
    Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
    Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
    Xue Q; Zhou Y; Wan C; Lv L; Chen B; Cao X; Ju G; Huang Y; Ni R; Mao G
    Exp Mol Pathol; 2013 Dec; 95(3):313-8. PubMed ID: 23920144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
    Galle E; Thienpont B; Cappuyns S; Venken T; Busschaert P; Van Haele M; Van Cutsem E; Roskams T; van Pelt J; Verslype C; Dekervel J; Lambrechts D
    Clin Epigenetics; 2020 Feb; 12(1):27. PubMed ID: 32059745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
    Ogawa T; Liggett TE; Melnikov AA; Monitto CL; Kusuke D; Shiga K; Kobayashi T; Horii A; Chatterjee A; Levenson VV; Koch WM; Sidransky D; Chang X
    Cell Cycle; 2012 Apr; 11(8):1656-63. PubMed ID: 22487682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
    Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
    Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression.
    Marwitz S; Heinbockel L; Scheufele S; Nitschkowski D; Kugler C; Perner S; Reck M; Ammerpohl O; Goldmann T
    Clin Epigenetics; 2017; 9():123. PubMed ID: 29209432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
    Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
    Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer.
    Ehrich M; Field JK; Liloglou T; Xinarianos G; Oeth P; Nelson MR; Cantor CR; van den Boom D
    Cancer Res; 2006 Nov; 66(22):10911-8. PubMed ID: 17108128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.